CLIC Sargent supports greater role for patients in developing value-based drugs pricing

CLIC Sargent is voicing its support for recommendations from a newly released report from Prostate Cancer UK, on value-based drugs pricing.

Commenting on the publication, CLIC Sargent Director of Communications and Campaigning, Liz North said: “CLIC Sargent is pleased to support the recommendations from this research which makes a strong case for ensuring cancer patients, including children, young people and their families, are included in discussions on how drugs are priced and assessed in the future.

“We hope that the Government will listen and ensure that patients are better represented in negotiations going forward.”

Read the full Prostate Cancer UK report.

Share